CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells

Chimeric antigen receptor (CAR)-T cells have not made significant progress in the treatment of acute myeloid leukemia (AML) in earlyclinical studies. This lack of progress could be attributed in part to the immunosuppressive microenvironment of AML, such as monocyte-like myeloid-derived suppressor c...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Xin, Xie, Danni, Sun, Rui, Lu, Wenyi, Xiao, Xia, Yu, Yibing, Meng, Juanxia, Zhao, Mingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461507/
https://www.ncbi.nlm.nih.gov/pubmed/37645216
http://dx.doi.org/10.1080/2162402X.2023.2248826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461507/
https://www.ncbi.nlm.nih.gov/pubmed/37645216
http://dx.doi.org/10.1080/2162402X.2023.2248826

Ejemplares similares